Latest from SCCA

Dr. Radich on Measuring MRD in Hematologic Malignancies

Jerald P. Radich, MD, discusses measuring minimal residual disease (MRD) in hematologic malignancies.

Dr. Higano on the State of Immunotherapy in Prostate Cancer

Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.

Dr. Swisher on the Limitations of HRD as a Biomarker in Ovarian Cancer

Elizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.

A Treatment Option in Myelofibrosis

This OncLive webinar will uncover the latest treatments in myelofibrosis by Bart Scott, MD. Join us on Tuesday, April 28, 2020 or Thursday, April 30, 2020 at 5 PM or 8 PM EDT.

Dr. Grivas on Potential Combinations With Cabazitaxel in Prostate Cancer

Petros Grivas, MD, PhD, discusses potential combination regimens with cabazitaxel in prostate cancer.

MRD Assessment Gains Momentum in Hematologic Malignancies

Jerald P. Radich, MD, discusses the growing importance of MRD assessment in the treatment paradigm for patients with hematologic malignancies.

Dr. Swisher on How the VELIA Trial Stands Out in Ovarian Cancer Research

Elizabeth M. Swisher, MD, discusses how the phase III VELIA/GOG-3005 trial compares with other trials examining up-front maintenance therapy in ovarian cancer.

Veliparib Improves PFS in BRCA Wild-Type Ovarian Cancer, Regardless of HRD Status

Veliparib plus chemotherapy extended progression-free survival for BRCA wild-type patients with high-grade serous carcinoma.

Next Page >>

Inside Oncology

View more videos >>